Vigmed publishes prospectus regarding the previously announced rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH
ACTION IS SUBJECT TO LEGAL RESTRICTIONS.
The prospectus regarding Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”)
rights issue has been approved and registered by the Swedish Financial
Supervisory Authority and is available on the Company’s website www.vigmed.com
and on Remium’s website www.remium.com.

Vigmed has engaged ABG Sundal Collier as financial advisors and Mannheimer
Swartling Advokatbyrå as legal advisor in connection with the rights issue.

Vigmed discloses the information in this press release pursuant to the Swedish
Securities Markets Act.
The information was provided for public release on November 20, 2015 at 17:35
CET.

Important information

This press release is not an offer regarding shares or other securities issued
by Vigmed Holding AB (publ) (the “Company”).

This press release may not be distributed in or into the United States, Canada,
Japan, Australia or in any other jurisdiction where such action is wholly or
partially subject to legal restrictions, or would require additional
prospectuses, registration or other measures than those required by Swedish law.
Nor may the information in this press release be forwarded or reproduced in a
manner that contravenes such restrictions or gives cause to such requirements.

No securities issued by the Company have been or will be registered under the
United States Securities Act of 1933, as amended (“Securities Act”) and may not
be offered, sold or otherwise transferred, directly or indirectly, in or into
the United States except under an available exemption from, or in a transaction
not subject to, the registration requirements under the Securities Act. No
public offering will be made in the United States.

In member states within the European Economic Area (EEA) (other than Sweden)
which have implemented Directive 2003/71/EC (the “Prospectus Directive”), this
press release is directed only at qualified investors as defined in the
Prospectus Directive.

This press release may contain certain forward-looking statements that reflect
the Company’s current views on future events as well as financial and
operational performance. Words such as “intend”, “assess”, “expect”, “may”,
“plan”, “believe”, “estimate” and other expressions entailing indications or
predictions of future development or trends, and which are not based on
historical facts, constitute forward-looking statements. Forward-looking
statements inherently involve both known and unknown risks and uncertainties as
they depend on future events and circumstances. Forward-looking statements
information is not a guarantee of future results or performance, and the actual
outcome may differ materially from the information set forth in the forward
-looking statements.

A prospectus prepared in accordance with the Prospectus Directive have been
published on November 20, 2015 and is, with certain restrictions, available at
www.vigmed.com.
For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Henrik Olsen +46 76
349 7364
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries and the associated risk of cross infections with blood
-borne infectious diseases by offering the market unique needle-protected
products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is
traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has
approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified
Advisor. Additional information about the company can be found on Vigmed’s
website: www.vigmed.com/investor